According to our latest research report, “Russian Pharma Sector Forecast to 2013”, the Government and other industrial regulatory bodies are taking numerous initiatives to ensure that the pharma industry in the country receives tremendous boost for the future. Understanding the pressing situation put forth by rising prevalence of lifestyle disease, such as diabetes, hypertension, cardiovascular disorders, etc., the authorities are determined to drive self-dependence of Russian pharma industry. As a result of proactive intervention, the state segment of the Russian pharma market is expected to grow at a CAGR of around 12% during the forecast period of 2011-2013.
All the measures being planned and introduced are the result of long standing dependence of Russia on imported pharma products, resulting into increased healthcare expenditure. The major focus so far has been the development of infrastructure of the domestic pharma industry, as the government wants the foreign players to establish their manufacturing units in Russia also. In a recent move, the Russian Ministry of Industry and Trade Ministry released a tender for the production of five imported drugs, which are not produced by domestic manufacturers, and are not protected by patents of foreign companies in Russia. Apart from all this, the Government is also adopting measures for improving the affordability of pharma products by enforcing the issuance of health coverage policies.
The report contains detailed market estimations and forecasts, all of which have been done after giving due consideration to the impact of the recession. Moreover, the report contains a detail overview of the potential and the future growth prospects of the overall industry and its various segments. Besides market drivers, our report covers the prominent roadblocks that are being faced by the Russian pharma industry.
Moreover, our report, “Russian Pharma Sector Forecast to 2013”, provides prudent analysis of authentic data, which has been procured through extensive research. The report also provides information on the leading drugs, segment-wise break up, and information on major therapy areas in the market. Additionally, the report discusses the latest industrial developments and competitive landscape to help clients gain a proper understanding of the market structure and its progress in the coming years.
For more information visit: http://www.rncos.com/Report/IM243.htm |
